The OncoArray Consortium: a network for understanding the genetic architecture of common cancers
METHODS: The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background.
RESULTS: The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis.
CONCLUSIONS: Results from these analyses will enable researchers to identify new susceptibility loci, perform fine mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental and lifestyle related exposures.
IMPACT: Ongoing analyses will shed light on etiology and risk assessment for many types of cancer.
History
Publication title
Cancer Epidemiology, Biomarkers and PreventionVolume
26Pagination
126-135ISSN
1055-9965Department/School
Menzies Institute for Medical ResearchPublisher
American Association for Cancer ResearchPlace of publication
United StatesRights statement
Copyright 2016 2016 American Association for Cancer ResearchRepository Status
- Restricted